Deals and Data

Deals and Data

Pfizer and Merck collaborate to research the potential of their two drugs in patients with ALK-positive advanced or metastatic non-small cell lung cancer. (PharmaTimes Online, 08/26/14)

Pfizer receives fast-track designation for its vaccine candidate against a potentially fatal infection that harms patients’ bowels. (The Wall Street Journal, 08/28/14)

Illumina expands BaseSpace cloud infrastructure to include category of internally developed research applications. (Genome Web, 08/29/14)

UCSD seeks participants in experimental drug trial; T-817MA protects rats’ brain cells from the memory-stealing effects of Alzheimer’s disease. (U-T San Diego, 08/30/14)

Novartis’ new heart failure drug LCZ696 reduces risk of death from cardiovascular causes, heart failure hospitalization. (PharmaTimes Online, 08/31/14)

Amgen seeks approval of evolocumab, an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver’s ability to remove bad cholesterol from blood. (RTT News, 09/02/14)

GE Healthcare wins approval of SenoClaire, a mammography device that produces three-dimensional images to detect breast cancer. (Reuters, 09/02/14)

Arena Pharmaceuticals’ APD811 granted orphan drug status for treatment of pulmonary arterial hypertension. (San Diego Business Journal, 09/02/14)

Merck and EMD Serono Research and Development Institute collaborate with Massachusetts General Hospital to research systemic lupus erythematosus and lupus nephritis pathogenesis. (GEN News, 09/02/14)

Isis Pharmaceuticals announces progress on cardiovascular drugs Kynamro and ISIS-APOCIIIRx , which employ gene-blocking antisense technology that stops diseases at the genetic level. (U-T San Diego, 09/02/14)

The Scripps Research Institute’s researchers identify unusually potent HIV antibody targeting a newly discovered vulnerable site. (U-T San Diego, 09/03/14)

Pfizer to promote Seebri and Ultibro via Novartis’ Breezhaler device for the treatment of patients with chronic obstructive pulmonary disease. (PharmaTimes Online, 09/04/14)

Halozyme Therapeutics’ PEGPH20 program granted fast track designation; evaluating effectiveness in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer. (Zacks, 09/05/14)

UC San Diego scientists discover breast cancer spreads less effectively to the lungs when an enzyme (Ubc13) regulating cell growth is blocked. (U-T San Diego, 09/07/14)

Astellas Pharma and Basilea Pharmaceutica’s NDA accepted for isavuconazole for the treatment of two types of invasive fungal infections in immunocompromised patients. (Zacks, 09/08/14)

Aethlon Medical and its diagnostic subsidiary, Exosome Sciences, develop and initially validate a diagnostic platform that could identify the presence of cancer in analyzed blood samples. (San Diego Business Journal, 09/08/14)

ViaCyte begins clinical trial of diabetes treatment derived from stem cells, the first such treatment ever tested in people. (U-T San Diego, 09/09/14)

U.S. FDA approves Orexigen Therapeutics’ weight loss pill, Contrave. (U-T San Diego, 09/10/14)